Conservation therapy in T1-T2 breast cancer: Past, current issues, and future challenges and opportunities

Cancer Journal

Volumn 9, Issue 6, 2003, Pages 442-453

  Perez, Carlos A ^a,b  

^a Washington University School of Medicine ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast conservation therapy; Carcinoma of the breast; Radiation therapy

Indexed keywords

ADOLESCENT; ADULT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ADJUVANT THERAPY; AGE; AGED; ARTICLE; BREAST TUMOR; INCIDENCE; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RADIATION RESPONSE; RISK FACTOR; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 33749561147     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200311000-00003     Document Type: Conference Paper

References (89)

1. Jenal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Keynes G. Conservative treatment of cancer of the breast. Br Med J 1937;3:643-647.
3. Mustakallio S. Über die mōglichkeiten der rō ntgentherapie bei der behandlung des brustkrebses. Acta Radiol 1945;26:503-522.
4. Mustakallio S. Conservative treatment of breast carcinoma: Review of 25 years follow-up. Clin Radiol 1972;23:110-116.
5. Rissanen PM. A comparison of conservative and radical surgery combined with radiotherapy in the treatment of stage I carcinoma of the breast. Br J Radiol 1969;42:423-426.
6. th ed. Baltimore: Lippincott Williams & Wilkins, 2004:1331.
7. Atkins H, Hayward JL, Klugman DJ et al. Treatment of early breast cancer: a report after 10 years of a clinical trial. Br Med J 1972; 2:423-429.
8. Veronesi U, Zucali R, DelVecchio M. Conservative treatment of breast cancer with the QUART technique. World J Surg 1985;9:676-681.
9. Fisher B, Joeng J-H, Anderson S et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-575.
10. Jacobson JA, Danforth DN, Cowan KH et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907-911.
11. van Dongen JA, Voogd AC, Fentiman IS et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial. J Natl Cancer Inst 2000;92:1143-1150.
12. Blichert-Toft M, Rose C, Andersen JA. et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Mongr 1992;11:19-25.
13. Sarrazin D, Le MG, Arrigada R et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989;14:177-184.
14. Beadle GF, Silver B, Botnick L et al. Cosmetic results following primary radiation therapy for early breast cancer. Cancer 1984;54:2911-2918.
15. Rose MA, Olivotto I, Cady B et al. Conservative surgery and radiation therapy for early breast cancer: Long-term cosmetic results. Ann Surg 1989;124:153-157.
16. th ed). Philadelphia: Lippincott-Raven, 1997:171-178.
17. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958;8:699-713.
18. Cox DR. Regression models and life tables. J Roy Stat Soc 1972; 34, Series B:187-220.
19. Dixon WJ. BMBP statistical software. Los Angeles, CA: University of California Press, 1982.
20. Dixon WJ. News for 1987 release of BMBP statistical software. Los Angeles, CA: University of California Press, 1986.
21. de Ru VJ, Hofman P, Struikmans H et al. Skin dose due to breast implantation for early breast cancer. In: Mould RF, Batterman JJ, Martinez AA et al, eds. Brachytherapy from Radium to Optimization. The Netherlands: Veenendaar, 1994:239-245.
22. Harris JR, Connolly JL, Schnitt SJ et al. The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg 1985;201:164-169.
23. Locker G, Sainsbury R, Cuzick J. Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy [abstract]. Br Ca Res Treat 2002;76[suppl 1]:S35.
24. Winchester DL. Data-based breast management. Presented at the 85th Annual Meeting of the American Radium Society, Houston, TX, April 27, 2003.
25. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 2002;94:490-496.
26. Bassett MT, Krieger N. Social class and black-white differences in breast cancer survival. Am J Public Health 1986;76:1400-1403.
27. Mandelblatt JS, Kerner JF, Hadley J et al. Variations in breast carcinoma treatment in older medical beneficiaries: is it black or white. Cancer 2002;95:1401-1414.
28. Harris JR, Lippman ME, Morrow M et al, eds. Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000.
29. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355:1757-1770.
30. Vinh-Hung V, Burzkowski T, Van de Steene J et al. Post-surgery in early breast cancer: survival analysis of registry data. Radiother Oncol 2002;64:281-290.
31. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000;88:114-123.
32. Roetzheim RG, Gonzalez EC, Ferrante JM et al. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 2000;89:2202-2213.
33. Simon MS, Severson RK. Racial differences in survival of female breast cancer in the Detroit metropolitan area. Cancer 1996;77:308-314.
34. Vernon SW, Tilley BC, Neale AV et al. Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer 1985;55:1563-1571.
35. Newman LA. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer 2002;94:2844-2854.
36. O'Malley CD, Le GM, Glaser SL et al. Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study. Cancer 2003;97:1303-1311.
37. Elmore JG, Moceri VM, Carter K et al. Breast carcinoma tumor characteristics in black and white women. Cancer 1998;83:2509-2515.
38. Ansell D, Whitman S, Lipton R et al. Race, income, and survival from breast cancer at two public hospitals. Cancer 1993;72:2974-2978.
39. Eidson M, Becker TM, Wiggins CL et al. Breast cancer among Hispanics, American Indians and non-Hispanic whites in New Mexico. Int J Epidemiol 1994;23:231-237.
40. Eley JW, Hill HA, Chen VW et al. Racial differences in survival from breast cancer: results of the National Cancer Institute black/white cancer survival study. JAMA 1994;272:947-954.
41. Franzini L, Williams AF, Franklin J et al. Effects of race and socioeconomic status on survival of 1332 black, Hispanic, and white women with breast cancer. Ann Surg Oncol 1997;4:111-118.
42. Gordon NH, Crowe JP, Brumberg DJ et al. Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol 1992;135:609-618.
43. Yood MU, Johnson CC, Blount A et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst 1999;91:1487-1491.
44. Albain KS, Alfred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? Mongr Natl Cancer Inst 1994;16:35-42.
45. Fowble BL, Schultz DJ, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994;30:23-33.
46. Host H, Lund E. Age as a prognostic factor in breast cancer [correction appears in Cancer 1986;58:996]. Cancer 1986;57:2217-2221.
47. Kroman N, Jensen M-B, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J 2000;320:474-479.
48. Walker RA, Lees E, Webb MB et al. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer 1996;74:1796-1800.
49. i9. Winchester DP, Osteen RT, Menck HR. The national cancer data base age. Cancer 1996;78:1838-1843.
50. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-1608.
51. Meric F, Mirza NQ, Vlastos G et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 2003;97:926-933.
52. Neuschatz AC, DiPetrillo T, Safaii H et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003;97:30-39.
53. Pezner RD, Wagman LD, Ben-Ezra J et al. Breast conservation therapy: local tumor control in patients with pathologically clear margins who receive 5000 cGy breast irradiation without local boost. Breast Cancer Res Treat 1994;32:261-267.
54. Schmidt-Ullrich R, Wazer DE, DiPetrillo T et al. Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys 1993; 27:545-552.
55. Vicini F, Baglan K, Kestin L et al. The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol 2002;12:31-39.
56. Romestaing P, Lehingue Y, Carrie C et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15:963-968.
57. Romestaing P, Lehingue Y, Delaunay D et al. Role of a 10-Gy boost in the conservation treatment of early breast cancer: results of a randomized clinical trial in Lyon, France [abstract]. Int J Radiat Oncol Biol Phys 2001;51[suppl 1]:3.
58. Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-1387.
59. Hayman J, Weeks J, Mauch P. Economics analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int J Radiat Oncol Biol Phys 1996;35:827-841.
60. Recht A, Harris JR, Come SE. Sequencing of irradiation and chemotherapy for early-stage breast cancer. Oncology 1994;8:19-37.
61. Buchholtz TA, Austin-Seymour MM, Moe RE et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993;26:23-35.
62. Recht A, Come SF, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356-1361.
63. Bellon JR, Come SE, Gelman RS et al. Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: updated results of a prospective randomized trial [abstract]. Int J Radiat Oncol Biol Phys 2001;51[suppl 1]:2.
64. Whelan T, MacKenzie R, Julian J et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143-1150.
65. Vicini FA, Sharpe M, Kestin L et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1336-1344.
66. Lomax AJ, Cella L, Weber D et al. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys 2003;55:785-792.
67. Lindsay KA, Wheldon EG, Deehan C et al. Radiation carcinogenesis modeling for risk of treatment-related second tumours following radiotherapy. Br J Radiol 2001;74:529-536.
68. Hall EJ, Wuu C-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-88.
69. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003;56:1038-1045.
70. Haffty BG: Radiation therapy and the risk of contralateral breast cancer. Int J Radiat Oncol Biol Phys 2003;56:920-921.
71. Kuske RR, Bolton JS, McKinnon WMP et al. 5-Year results of a prospective phase II trial of wide-volume brachytherapy as the sole method of breast irradiation in Tis, T1, T2, N0, 1 breast cancer [abstract]. Radiother Oncol 2000;55[suppl 1]:26.
72. Keisch M, Vicini F, Kuske RR et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003;55:289-293.
73. Veronesi U, Orecchia R, Luini A et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 2001;37:2178-2183.
74. Valdya JS, Joseph D, Hilaris B et al. Targeted intraoperative radiotherapy (TARGIT) for breast cancer [abstract]. Breast Cancer Res Treat 2002;[suppl 1]:S18.
75. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 1999;354:896-900.
76. Arthur DW, Arnfield MR, Warwicke LA et al. Internal mammary node coverage: an investigation of presently accepted techniques. Int J Radiat Oncol Biol Phys 2000;48:139-146.
77. Chung MA, DiPetrillo T, Hernandez S et al. Treatment of the axilla by tangential breast radiotherapy in women with invasive breast cancer. Am J Surg 2002;184:401-402.
78. Goodman RL, Grann A, Saracco P et al. The relationship between radiation fields and regional lymph nodes in carcinoma of the breast. Int J Radiat Oncol Biol Phys 2001;50:99-105.
79. Mansur DB, Kong F, Klein EE et al. Three-dimensional localization of internal mammary and axillary lymphatic regions and the significance on optimized breast cancer treatment planning [abstract]. Int J Radiat Oncol Biol Phys 2001;51[suppl 1]:248.
80. Fisher B, Dignam J, Tan-Chiu E et al. Prognosis and treatment of patients with breast tumors of one centimeter of less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93:112-120.
81. Dehdashti F, Siegel BA. Evaluation of breast and gynecologic cancers by positron emission tomography. Semin Roentgenol 2002;37:151-168.
82. Adler LP, Crowe JP, Al-Kaisi NK et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
83. Crippa F, Agresti R, Seregni E et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4-8.
84. Crowe JP Jr, Adler LP, Shenk RR et al. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-140.
85. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618-623.
86. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588-1593.
87. Greco M, Crippa F, Agresti R et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:630-635.
88. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
89. Ganz PA, Rowland JH, Desmond K et al: Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-514.